Jeddah Scan Radiology Center in Saudi Arabia now offers the EOS imaging platform
PARIS--(BUSINESS WIRE)--EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today its entry into the Middle East market with a first installation in Saudi Arabia. Jeddah Scan Radiology Center’s commitment to dose reduction and 3D modeling resulted in the decision to exclusively offer EOS exams for axial skeleton diagnosis, planning and control.
The EOS system installed at the Jeddah Scan Radiology Center in Saudi Arabia is the first in the Middle East. The Center serves referring physicians who specialize in orthopedics, rheumatology and pediatrics at several key regional hospitals. Now that the EOS technology is available, the Jeddah Scan Center intends to reach a broad base of prescribers who are looking for the added value that EOS exams provide for better, less irradiating treatment of patients in an urban area of 3.4 million.
The EOS platform provides 2D and 3D full-body, stereo-radiographic images of patients in functional positions. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose system, recently cleared by the Food and Drug Administration, marks another important step towards the ALARA principle (As Low As Reasonably Available). This latest technology has made the dose for a pediatric spine follow-up exam equivalent to a week of natural background radiation on Earth.
Marie Meynadier, CEO of EOS imaging said, “We’re excited to enter the Middle Eastern market, especially in a city like Jeddah, Saudi Arabia, which has come to be considered a center of excellence in medical care. As part of our commitment to our shareholders and future patients, we are thrilled to see the EOS platform reach a new and important market with significant potential.”
For more information, please visit www.eos-imaging.com.
EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.
EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
About EOS imaging
EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 48 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2014 revenues of €20.1 million and employs 107 people including an R&D team of 39 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.
Contacts
EOS imaging
Anne Renevot, CFO, +33 (0)1 55 25 61 24
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent, +33 (0)1 44 71 94 91
eosimaging@newcap.fr
or
The Ruth Group (US)
Press relations
Joanna Zimmerman, 646-536-7006
jzimmerman@theruthgroup.com
Help employers find you! Check out all the jobs and post your resume.